{"id":1637,"date":"2012-05-17T10:38:59","date_gmt":"2012-05-17T00:38:59","guid":{"rendered":"http:\/\/www.spinalcure.org.au\/?p=1637"},"modified":"2012-05-17T10:38:59","modified_gmt":"2012-05-17T00:38:59","slug":"stemcells-inc-reports-positive-interim-safety-data-from-spinal-cord-injury-trial","status":"publish","type":"post","link":"https:\/\/www.spinalcure.org.au\/research\/stemcells-inc-reports-positive-interim-safety-data-from-spinal-cord-injury-trial\/","title":{"rendered":"StemCells, Inc. reports positive interim safety data from spinal cord injury trial"},"content":{"rendered":"

StemCells, Inc. has announced completion of the first planned interim safety review of the company’s Phase I\/II spinal cord injury clinical trial, which indicated that the surgery, immunosuppression and the cell transplants have been well-tolerated. The trial, which is designed to evaluate the safety and preliminary efficacy of the their proprietary HuCNS-SC\u00ae cells, represents the first time that neural stem cells have been transplanted as a potential therapeutic agent for spinal cord injury.<\/p>\n

Read more…<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

\n
\nStemCells, Inc. has announced completion of the first planned interim safety review of the company’s Phase I\/II spinal cord injury clinical trial, which indicated that the surgery, immunosuppression and the cell transplants have been well-tolerated. The trial, which is designed…\n<\/div>\n